Osiris Therapeutics Adds TruSkin™ to it’s Wound Care Portfolio
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today the launch of TruSkin™, a cryopreserved, living skin allograft.
TruSkin has been developed to provide healthcare professionals a new option for treating large, chronic wounds in the Hospital Outpatient, Private Office, and/or Surgical Settings, where allograft options are limited and reimbursement pressures are high. Specifically in the HOPD setting, it has become common to relegate product usage to those products that are under their assigned bundled payment amounts. Currently, patients with larger wounds are limited in the offerings of advanced skin substitutes. Osiris’ strategy is to provide a larger-sized, high quality graft that fits within the Medicare bundled payment amounts to ensure that providers have an Osiris product option despite wound size. Osiris’ large TruSkin allograft will ensure that physicians have a larger-sized, high quality graft for patients regardless of wound size.
Standard industry processing and cryopreservation methods for skin allografts were optimized by Osiris to maximize post-thaw cell viability. Characterization studies demonstrate that the new proprietary TruSkin process maintains key structural and functional properties of fresh skin allografts to promote proper wound closure. Consistent with its evidence based approach, Osiris plans to introduce a robust scientific and clinical program for TruSkin, including multiple randomized controlled trials, comparative studies, case studies, and clinical and scientific posters and abstracts.
“Osiris is committed to developing products that address unmet medical needs,” said Alla Danilkovitch, Ph.D., Chief Scientific Officer. “This new skin allograft, TruSkin, provides structural and functional properties similar to fresh skin that are essential for the repair of chronic wounds in patients.”
TruSkin is a split-thickness, cryopreserved skin allograft that is offered by Osiris to address unmet medical needs of chronic wounds. TruSkin retains the extracellular matrix, growth factors, and endogenous living skin cells of native tissue, making it an alternative to fresh skin allograft. TruSkin is optimally meshed to cover more wound area than competing skin allografts, while still allowing for proper wound drainage. TruSkin can be used to repair acute and chronic wounds, including but not limited to: diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, and wounds with exposed bone and tendon. TruSkin will be available in multiple sizes and have a 5-year shelf life when stored at or below -40°C.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is the world leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4® , a viable bone matrix, Cartiform®, a viable osteochondral allograft, Grafix®, a cryopreserved placental membrane and TruSkin, a viable human skin allograft.Osiris, Grafix and Cartiform are registered trademarks of Osiris Therapeutics, Inc; TruSkin is a trademark of Osiris Therapeutics, Inc. BIO4 is a registered trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company’s website, www.Osiris.com. (OSIR-G)